Schmedt N, Alhamdow A, Tskhvarashvili G, Saarelainen L, et al. Post-authorisation safety study to assess the risk of urinary tract cancer in people with type 2 diabetes initiating empagliflozin: A multi-country European study. Diabetes Obes Metab 2025 Jun 13. doi: 10.1111/dom.16477.
PMID: 40511488